Patents by Inventor Emiko Murayama

Emiko Murayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12097189
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in fasted state is 400 ng/ml or less, is disclosed.
    Type: Grant
    Filed: March 22, 2024
    Date of Patent: September 24, 2024
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Soichiro Nakamura, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Kazuhiro Sako
  • Publication number: 20240277675
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-((2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa's or more at a 5% aqueous solution at 25 C is disclosed.
    Type: Application
    Filed: March 22, 2024
    Publication date: August 22, 2024
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • Patent number: 12059409
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl] acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.
    Type: Grant
    Filed: March 22, 2024
    Date of Patent: August 13, 2024
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • Patent number: 11707451
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: July 25, 2023
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Soichiro Nakamura, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Kazuhiro Sako
  • Publication number: 20210322387
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.
    Type: Application
    Filed: November 19, 2020
    Publication date: October 21, 2021
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • Publication number: 20210085654
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Inventors: YUUKI TAKAISHI, SOICHIRO NAKAMURA, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, KAZUHIRO SAKO
  • Patent number: 10842780
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 24, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • Publication number: 20170231965
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Application
    Filed: February 14, 2017
    Publication date: August 17, 2017
    Applicant: ASTELLAS PHARMA INC.
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • Patent number: 9675549
    Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Ambit Biosciences Corporation
    Inventors: Shinsuke Oba, Hiroyasu Toyota, Satomi Ikeuchi, Takumi Hara, Emiko Murayama, Kei Motonaga
  • Publication number: 20160184275
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Application
    Filed: September 28, 2009
    Publication date: June 30, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • Publication number: 20150250720
    Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 10, 2015
    Inventors: Shinsuke Oba, Hiroyasu Toyota, Satomi Ikeuchi, Takumi Hara, Emiko Murayama, Kei Motonaga
  • Publication number: 20100144807
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 5 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Application
    Filed: September 28, 2009
    Publication date: June 10, 2010
    Applicant: Astellas Pharma Inc
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako